BioSpace News Archive

Intercept Pharmaceuticals, Inc. announced new sub-analyses from its Phase 3 POISE trial in primary biliary cholangitis showing the effect of obeticholic acid across a number of key biomarkers of liver health in people living with PBC will be presented at the European Association for the Study of the Liver Congress 2024 being held June 5-8, 2024, in Milan, Italy.

The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS2Bio Inc.

Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria’s common stock on June 3, 2024 under Astria’s 2022 Inducement Stock Incentive Plan.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024.

Eli Lilly and Company announced that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company’s Executive Committee, effective July 22, 2024.

Capricor Therapeutics today announced positive 3-year results from the ongoing HOPE-2 open-label extension (OLE) study with CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD).

Zymo Research, a leader in biotechnological advancement has launched a new nuclease called PureRec Duplex-Specific Nuclease that selectively digests double stranded DNA.

ValGenesis Inc. announced the launch of VLMS 5.0, the revolutionary new version of its flagship digital validation lifecycle management software poised to transform the industry’s approach to digital transformation.

Microbot Medical Inc. announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock.

Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved, on May 22, 2024, inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan.